Pharmaceuticals

Multiple Sclerosis Treatment Market Size and Demand Forecast 2026–2030

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the multiple sclerosis treatment market from 2026–2035 with trusted insights from The Business Research Company

How is the Multiple Sclerosis Treatment Market size predicted to change over the forecast window of 2026–2035?

The multiple sclerosis treatment market has demonstrated significant expansion in recent years. Its size is anticipated to rise from $26.13 billion in 2025 to $27.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.0%. This past growth can be attributed to factors such as advancements in autoimmune disease research, the introduction of injectable MS therapies, the expansion of neurology clinics, widespread hospital-based treatment options, and the ongoing development of biologics.

The multiple sclerosis treatment market size is projected for consistent expansion over the upcoming years, reaching $33.02 billion by 2030, driven by a compound annual growth rate (CAGR) of 4.7%. This anticipated growth during the forecast period is influenced by factors such as the adoption of oral therapies, the rise of home-based MS care, long-term disease management strategies, advancements in imaging diagnostics, and personalized immunotherapy. Key trends emerging in this period involve the broadening of disease-modifying therapies, an increase in oral MS medications, a greater emphasis on early diagnosis, the growing application of monoclonal antibodies, and tailored treatment approaches.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24612&type=smp

Which Drivers Are Contributing To The Expansion Of The Multiple Sclerosis Treatment Market?

The increasing occurrence of neurological disorders is anticipated to stimulate the expansion of the multiple sclerosis treatment market moving forward. Neurological disorders are medical conditions that impact the brain, spinal cord, and nerves throughout the body, leading to difficulties with movement, communication, behavior, or bodily functions. The rise in these conditions is attributable to an aging populace, as longer lifespans heighten the risk of age-related ailments like Alzheimer’s. Multiple sclerosis treatment assists in managing neurological disorders by targeting the immune system to diminish inflammation, avert nerve damage, and alleviate symptoms, thereby enhancing the quality of life for patients. For instance, in October 2023, according to the World Federation of Neurology, a UK-based association of national neurological societies, more than 40% of the global population currently experiences some form of neurological condition, and this burden is expected to nearly double by 2050. Consequently, the rising prevalence of neurological disorders is propelling the growth of the multiple sclerosis treatment market.

What Segment Classifications Make Up The Multiple Sclerosis Treatment Market?

The multiple sclerosis treatment market covered in this report is segmented –

1) By Treatment Type: Immunomodulators, Corticosteroids, Symptomatic Treatments, Monoclonal Antibodies, Oral Therapies

2) By DiseaseType: Clinically Isolated Syndrome, Relapse-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

3) By Route Of Administration: Oral, Injectable, Intravenous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Immunomodulators: Interferon Beta-1A, Interferon Beta-1B, Glatiramer Acetate

2) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone

3) By Symptomatic Treatments: Muscle Relaxants, Antidepressants, Anticonvulsants, Bladder Dysfunction Drugs

4) By Monoclonal Antibodies: Natalizumab, Ocrelizumab, Alemtuzumab, Ofatumumab

5) By Oral Therapies: Fingolimod, Dimethyl Fumarate, Teriflunomide, Cladribine, Siponimod

Which Innovation Trends Are Advancing Developments Within The Multiple Sclerosis Treatment Market?

Leading companies in the multiple sclerosis treatment market are creating advanced products, such as monoclonal antibody medications, to improve treatment efficacy and patient results. Monoclonal antibody drugs are laboratory-produced molecules designed to target specific antigens, and in multiple sclerosis, they aid by diminishing inflammation and preventing immune cells from attacking nerve fibers, thereby regulating disease progression. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (Ocrelizumab) for the treatment of multiple sclerosis (MS). This drug targets CD20-positive B cells, which helps in reducing inflammation and nerve damage in MS. It stands as the first approved therapy for both relapsing and primary progressive types of MS, substantially lowering relapse rates and slowing the advancement of disability with the convenience of twice-yearly infusions.

Which Leading Companies Dominate The Multiple Sclerosis Treatment Market Share?

Major companies operating in the multiple sclerosis treatment market are Biogen Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Teva Pharmaceutical Industries Ltd, Sanofi Genzyme, Merck KGaA, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson (Janssen), TG Therapeutics Inc., Acorda Therapeutics Inc., Takeda Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Almirall S.A., Otsuka Pharmaceutical Co. Ltd., Apitope International NV, BrainStorm Cell Therapeutics Inc., Roche Diagnostics, InnoCare Pharma, NervGen Pharma Corp., Receptos Inc., Biogen Idec International GmbH, MedDay Pharmaceuticals SA, Genentech Inc., Roche Holding AG

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-treatment-global-market-report

How Does The Multiple Sclerosis Treatment Market Perform Across Major Global Regions?

North America was the largest region in the multiple sclerosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Multiple Sclerosis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24612&type=smp

Browse Through More Reports Similar to the Global Multiple Sclerosis Treatment Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795